学术探索
学术期刊
新闻热点
数据分析
智能评审

Update of the in vitro activity of daptomycin tested against 6710 Gram-positive cocci isolated in North America (2006)

被引：35
作者：
Castanheira, Mariana [1 ]
Jones, Ronald N. [1 ,2 ]
Sader, Helio S. [1 ,3 ]
机构：
[1] JMI Labs, N Liberty, IA 52317 USA
[2] Tufts Univ, Sch Med, Boston, MA 02111 USA
[3] Univ Fed Sao Paulo, Div Infect Dis, BR-04023900 Sao Paulo, Brazil
来源：
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE | 2008年 / 61卷 / 02期
关键词：
daptomycin; MRSA; vancomycin resistance;
D O I：
10.1016/j.diagmicrobio.2008.01.016
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
Gram-positive bacterial strains (6710) consecutively collected during 2006 in hospitals located in the United States and Canada were tested by reference broth microdilution methods against daptomycin and comparison agents. Only 1 Staphylococcus aureus strain (0.01%) had nonsusceptible daptomycin MIC value as specified by published break points. S. aureus daptomycin MIC distributions from 2006 as compared with those of previous years did not show "MIC creep". Resistance to other compounds, such as vancomycin, oxacillin and penicillin, did not adversely influence daptomycin activity. Daptomycin remains highly active against clinical Gram-positive isolates collected in North America. (C) 2008 Elsevier Inc. All rights reserved.
引用
收藏
页码：235 / 239
页数：5
相关论文
共 12 条
[1]  
[Anonymous], 2006, METH DIL ANT SUSC TE
[2]   Perspectives on daptomycin resistance, with emphasis on resistance in Staphylococcus aureus [J].
Boucher, Helen W. ;
Sakoulas, George .
CLINICAL INFECTIOUS DISEASES, 2007, 45 (05) :601-608
[3]   Daptomycin: Another novel agent for treating infections due to drug-resistant gram-positive pathogens [J].
Carpenter, CF ;
Chambers, HF .
CLINICAL INFECTIOUS DISEASES, 2004, 38 (07) :994-1000
[4]  
*CLIN LAB STAND I, 2007, M100S17 CLIN LAB S S
[5]   Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus [J].
Friedman, L ;
Alder, JD ;
Silverman, JA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (06) :2137-2145
[6]   Assessment of two commercial susceptibility test methods for determination of daptomycin MICs [J].
Jorgensen, JH ;
Crawford, SA .
JOURNAL OF CLINICAL MICROBIOLOGY, 2006, 44 (06) :2126-2129
[7]   Daptomycin: a rapidly bactericidal lipopeptide for the treatment of Gram-positive infections [J].
Konafani, Zeina A. ;
Corey, G. Ralph .
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2007, 5 (02) :177-184
[8]   Daptomycin nonsusceptibility in Staphylococcus aureus with reduced vancomycin susceptibility is independent of alterations in MprF [J].
Pillai, Satish K. ;
Gold, Howard S. ;
Sakoulas, George ;
Wennersten, Christine ;
Moellering, Robert C., Jr. ;
Eliopoulos, George M. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (06) :2223-2225
[9]   The activity of daptomycin against wild-type Staphylococcus aureus and strains with reduced susceptibility to vancomycin [J].
Sader, Helio S. ;
Jones, Ronald N. .
CLINICAL INFECTIOUS DISEASES, 2006, 43 (06) :798-799
[10]   Daptomycin bactericidal activity and correlation between disk and broth microdilution method results in testing of Staphylococcus aureus strains with decreased susceptibility to vancomycin [J].
Sader, Helio S. ;
Fritsche, Thomas R. ;
Jones, Ronald N. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (07) :2330-2336
12